This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stein, R. Articles by Goldenberg, D. M. Search for Related Content PubMed PubMed Citation Articles by Stein, R. Articles by Goldenberg, D. M.

Human Lung Carcinoma Monoclonal Antibody Specific for the Thomsen-Friedenreich Antigen¹

Center for Molecular Medicine and Immunology, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103

A monoclonal antibody, RS1-114, was raised against the human adenocarcinoma of the lung cell line A549. By studying the reactivity of RS1-114 with A549 cells following chemical and enzymatic treatments, it was shown that the epitope is a galactose-containing carbohydrate, which is devoid of sialic acid. Hemagglutination of desialylated RBCs, enzyme-linked immunosorbent assay studies with glycoprotein antigens before and after desialylation, and competition studies using peanut agglutinin indicate that monoclonal antibody RS1-114 recognizes the Thomsen-Friedenreich antigen, a cryptic determinant on human erythrocytes which can be exposed by neuraminidase treatment. It is expressed in an unhidden form on a large percentage of carcinomas and is therefore an important human tumor marker. RS1-114 is reactive with cryptic determinants of the Thomsen-Friedenreich antigen on white blood cells as well as red blood cells, and it reacts with unhidden determinants on human tumor cell lines. The number of binding sites on carcinoma cells is further increased by neuraminidase treatment. By immunohistochemical staining, it was shown that 75% of the human tumors tested are reactive with RS1-114. These include tumors of the breast, colon, lung, kidney, ovary, and rectum.

¹ Supported in part by NIH Grant CA 39841.

² To whom requests for reprints should be addressed, at the Center for Molecular Medicine and Immunology, 1 Bruce Street, Newark, NJ 07103.

Received 7/ 7/88. Revised 9/22/88. Accepted 9/29/88.

This article has been cited by other articles:

				R. Stein, M. R. Smith, S. Chen, M. Zalath, and D. M. Goldenberg Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines Clin. Cancer Res., April 15, 2009; 15(8): 2808 - 2817. [Abstract] [Full Text] [PDF]

				R. Stein, Z. Qu, S. Chen, D. Solis, H. J. Hansen, and D. M. Goldenberg Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab Blood, October 15, 2006; 108(8): 2736 - 2744. [Abstract] [Full Text] [PDF]

				R. Stein, Z. Qu, T. M. Cardillo, S. Chen, A. Rosario, I. D. Horak, H. J. Hansen, and D. M. Goldenberg Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies Blood, December 1, 2004; 104(12): 3705 - 3711. [Abstract] [Full Text] [PDF]

				R. Stein, Z. Qu, S. Chen, A. Rosario, V. Shi, M. Hayes, I. D. Horak, H. J. Hansen, and D. M. Goldenberg Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin's Lymphoma Clin. Cancer Res., April 15, 2004; 10(8): 2868 - 2878. [Abstract] [Full Text] [PDF]

				Y. Xu, S. J. Gendler, and A. Franco Designer Glycopeptides for Cytotoxic T Cell-based Elimination of Carcinomas J. Exp. Med., March 1, 2004; 199(5): 707 - 716. [Abstract] [Full Text] [PDF]

				B.-L. Wang, G. F. Springer, and S. C. Carlstedt Quantitative Computerized Image Analysis of Tn and T (Thomsen-Friedenreich) Epitopes in Prognostication of Human Breast Carcinoma J. Histochem. Cytochem., October 1, 1997; 45(10): 1393 - 1400. [Abstract] [Full Text] [PDF]